Cigna®

Fax completed form to: (855) 840-1678
If this is an URGENT request, please call (800) 882-4462
(800.88.CIGNA)

# Cerezyme (imiglucerase), Elelyso (taliglucerase alfa), VPRIV (velaglucerase alfa)

| PHYSICIAN INFORMATION | | | PATIENT INFORMATION | | |
|---|---|---|---|---|---|
| * Physician Name: | | | *Due to privacy regulations we will not be able to respond via fax with the outcome of our review unless all asterisked (*) items on this form are completed.* | | |
| Specialty: | * DEA, NPI or TIN: | | | | |
| Office Contact Person: | | | * Patient Name: | | |
| Office Phone: | | | * Cigna ID: | * Date of Birth: | |
| Office Fax: | | | * Patient Street Address: | | |
| Office Street Address: | | | City: | State: | Zip: |
| City: | State: | Zip: | Patient Phone: | | |

**Urgency:**
☐ Standard ☐ Urgent (In checking this box, I attest to the fact that applying the standard review time frame may seriously jeopardize the customer's life, health, or ability to regain maximum function)

**Medication Requested:** ☐ Cerezyme 400 unit vial ☐ Elelyso 200 unit vial ☐ VPRIV 400 unit vial

Dose: Frequency of therapy: Duration of therapy: ICD10:

What is your patient's current weight? _____ lb/kg

Is this a new start or continuation of therapy? If your patient has already begun treatment with drug samples, please choose "new start of therapy". ☐ new start of therapy ☐ continued established therapy Start date:

**Where will this medication be obtained?**
☐ Accredo Specialty Pharmacy**
☐ Hospital Outpatient
☐ Retail pharmacy
☐ Other (please specify):
☐ Home Health / Home Infusion vendor
☐ Physician's office stock (billing on a medical claim form)
***Cigna's nationally preferred specialty pharmacy*

***Medication orders can be placed with Accredo via E-prescribe - Accredo (1620 Century Center Pkwy, Memphis, TN 38134-8822 | NCPDP 4436920), Fax 888.302.1028, or Verbal 866.759.1557*

**Facility and/or doctor dispensing and administering medication:**
Facility Name: State: Tax ID#:
Address (City, State, Zip Code):

**Where will this drug be administered?**
☐ Patient's Home
☐ Hospital Outpatient
☐ Physician's Office
☐ Other (please specify):

***NOTE:** Per some Cigna plans, infusion of medication MUST occur in the least intensive, medically appropriate setting.*

Is this patient a candidate for re-direction to an alternate setting (such as alternate infusion site, physician's office, home) with assistance of a Specialty Care Options Case Manager? ☐ Yes ☐ No (provide medical necessity rationale):

Is the requested medication for a chronic or long-term condition for which the prescription medication may be necessary for the life of the patient? ☐ Yes ☐ No

**What is the indication or diagnosis?**

☐ Gaucher disease Type 1 – Please Note: Type 1 Gaucher disease is also known as non-neuronopathic Gaucher disease
☐ Gaucher disease Type 3 – Please Note: Type 3 Gaucher disease is also known as chronic neuronopathic Gaucher disease.
☐ All other indications or diagnoses

**Clinical Information:**

Is the requested medication being prescribed by or in consultation with a geneticist, endocrinologist, a metabolic disorder sub-specialist, or a physician who specializes in the treatment of lysosomal storage disorders? Yes ☐ No ☐

Will the requested medication be used with other approved therapies for Gaucher disease? - Please note: Examples of medications FDA-approved for Gaucher disease include Cerdelga (eliglustat capsules), Cerezyme (imiglucerase injection), Elelyso (taliglucerase alfa injection), Vpriv (velaglucerase alfa injection), and Zavesca (miglustat capsules). Yes ☐ No ☐

Is documentation being provided that the diagnosis has been established by the demonstration of deficient beta-glucocerebrosidase activity in leukocytes or fibroblasts? PLEASE NOTE: Medical documentation specific to your response must be attached to this case or your request may be denied. Documentation may include, but is not limited to, chart notes, laboratory results, medical test results, claims records, prescription receipts, and/or other information. All documentation must include patient-specific identifying information. Yes ☐ No ☐

(if no) Is documentation being provided that the diagnosis has been established by molecular genetic testing documenting biallelic pathogenic variants in the glucocerebrosidase (GBA) gene? PLEASE NOTE: Medical documentation specific to your response must be attached to this case or your request may be denied. Documentation may include, but is not limited to, chart notes, laboratory results, medical test results, claims records, prescription receipts, and/or other information. All documentation must include patient-specific identifying information. Yes ☐ No ☐

(if Cerezyme requested OR Elelyso/VPRIV requested and has Type 3 Gaucher disease) Is the requested medication being used for the management of neurological manifestations? - Please Note: Examples of neurological manifestations may include abnormal ocular movement, auditory impairment, cognitive impairment, and seizures. Yes ☐ No ☐

(if Elelyso/VPRIV requested and NOT being used for neuro manifestations) Is the requested medication being used for the management of impaired growth, hematologic, or visceral symptoms? Please Note: Examples of visceral symptoms include splenomegaly and hepatomegaly. Examples of hematologic symptoms include anemia and thrombocytopenia. Yes ☐ No ☐

**Additional pertinent information:**

Attestation: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan or insurer its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

**Prescriber Signature:**_____ **Date:**_____

**Save Time! Submit Online at: www.covermymeds.com/main/prior-authorization-forms/cigna/ or via SureScripts in your EHR.**

*Our standard response time for prescription drug coverage requests is 5 business days. If your request is urgent, it is important that you call us to expedite the request. View our Prescription Drug List and Coverage Policies online at cigna.com.*

v050126